Verastem, Inc. - Common Stock (NQ:VSTM)

9.850 +0.080 (+0.82%)

Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why Is Verastem (VSTM) Stock Down 62% Today? ↗

May 24, 2024

Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data.

Via InvestorPlace

Dow Surges 50 Points; US Durable Goods Orders Increase In April ↗

May 24, 2024

Via Benzinga

Topics Stocks

What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? ↗

May 24, 2024

Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant...

Via Benzinga

Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗

May 24, 2024

Via Benzinga

VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 ↗

May 09, 2024

VSTM stock results show that Verastem beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Recap: Verastem Q4 Earnings ↗

March 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 24, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

May 24, 2024

We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!

Via InvestorPlace

Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

May 24, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

May 23, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

May 09, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference

May 07, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

April 18, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2024

From Verastem Oncology

Via Business Wire

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

March 18, 2024

From Verastem Oncology

Via Business Wire

VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 ↗

March 14, 2024

VSTM stock results show that Verastem missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

March 14, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

March 11, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

March 05, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

March 05, 2024

From Verastem Oncology

Via Business Wire

Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 12, 2024

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and...

Via Benzinga

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 ↗

February 07, 2024

Discover AI's top stock selections, meticulously analyzed for 2024, promising more than just returns but a revolution in your portfolio.

Via InvestorPlace

Topics Artificial Intelligence

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

January 29, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

January 18, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 11, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 05, 2024

From Verastem Oncology

Via Business Wire

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

December 18, 2023

From Verastem Oncology

Via Business Wire

3 Off-the-Beaten-Path Stocks Poised for Substantial Growth ↗

December 13, 2023

Although there’s safety in numbers, many times, you need to consider uncommon stocks to buy for growth for robust upside.

Via InvestorPlace

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

December 13, 2023

From Verastem Oncology

Via Business Wire

Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential ↗

December 03, 2023

Although even so-called penny stocks with potential carry dramatic risks, these four-baggers benefit from analyst backing.

Via InvestorPlace

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.